Rallybio Completes Key FNAIT Risk Study, Laying Groundwork for Future Market Moves

Rallybio Corporation (RLYB) announced an update on their ongoing clinical study.

The Rallybio (RLYB) study, officially titled “A Prospective, Natural History Study to Assess the Occurrence of HPA-1a Alloimmunization in Women Identified at Higher Risk for Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT),” tracks how often this rare pregnancy-related blood disorder risk occurs. It aims to map risk in a broad group of women, which is key groundwork for future prevention drugs.

The study is not testing a drug or biologic. Instead, the only intervention is structured clinical data collection, including lab work, vital signs, and genetic and antibody tests, to better understand who is at higher risk and how the condition develops over time.

This is an observational cohort study with a prospective design, meaning researchers follow pregnant women over time without changing their care. There is no randomization or blinding, and the main goal is to describe natural patterns of disease and immune response in a real-world setting.

The trial was first submitted on 7 April 2022, marking the formal start of this data effort for Rallybio. The last update was filed on 4 March 2026, signaling that the study is now listed as completed and the dataset should be locked or close to ready for analysis.

For investors, completion of this natural history study is an important de-risking step for Rallybio’s FNAIT program, which underpins the future market case for any prophylactic therapy they develop. Strong, clear data on disease frequency and risk groups could support pricing, payer discussions, and valuation, especially relative to any competing maternal-fetal immunology players.

The study has been completed and recently updated on the registry, with more details available on the ClinicalTrials portal.

To learn more about RLYB’s potential, visit the Rallybio Corporation drug pipeline page.